Therefore, blocking the 4-1BB signaling pathway with antagonistic mAb or inhibitors may be a valuable therapeutic tool for the control of JE progression via enhanced IFN-I and IFN-II responses. This evidence concerns the gene TNFRSF9 and Japanese encephalitis.